{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:24:41Z","timestamp":1787120681497,"version":"build-2736575974"},"reference-count":53,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board Ireland","doi-asserted-by":"publisher","award":["IDS-TILDA-2025-001"],"award-info":[{"award-number":["IDS-TILDA-2025-001"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Panoz Pharmaceutical Innovation PhD Scholarship"}],"content-domain":{"domain":["hrbopenresearch.org"],"crossmark-restriction":false},"short-container-title":["HRB Open Res"],"abstract":"<ns5:p>Background Adults with intellectual disability age differently, with differing comorbid conditions, prescribing patterns, and medication management considerations than the general population. The Optimising Pharmaco-Therapy and Improving Medication for Ageing with Intellectual Disability (OPTIMA-ID) tool is a newly described set of prescribing criteria developed by expert consensus designed specifically for medicines optimisation in older adults with intellectual disability. The Intellectual Disability Supplement to The Irish Longitudinal Study on Ageing (IDS-TILDA) is key source of observational evidence for medicines in this population. OPTIMA-ID must be tested in the population of older adults with intellectual disability to investigate applicability of the tool for medicines optimisation in clinical practice and to describe potentially inappropriate prescribing for the first time in Ireland. Methods To design a method for the application of OPTIMA-ID to IDS-TILDA data for the first time, the OPTIMA-ID tool was operationalised by translating the criteria into codable statements. These were used to develop bespoke functions in the programming language R for application to the health, behavioural and medicines data from the fifth Wave of IDS-TILDA data collection. Results For the Wave 5 IDS-TILDA dataset, 52 of 67 (78%) OPTIMA-ID criteria were applicable. They were translated into codable statements and built into functions in R for computerised application to the dataset. These functions produce an output of either True or False depending on whether the conditions for each OPTIMA-ID criteria are met, and identify the responsible medicine\u2019s Anatomical Therapeutic Chemical code where relevant. Conclusion This protocol describes a method for the application of a novel medicines optimisation tool in a population of older adults with intellectual disability in Ireland, using accurate, computational methods to identify and describe potentially inappropriate prescribing in this population. This will be first study to use OPTIMA-ID to demonstrate its applicability in its intended target population.<\/ns5:p>","DOI":"10.12688\/hrbopenres.14510.1","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:24:06Z","timestamp":1785320646000},"page":"81","update-policy":"https:\/\/doi.org\/10.12688\/hrbopenres.crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A protocol for application of OPTIMA-ID to identify potentially inappropriate prescribing in a cohort of older adults with intellectual disability"],"prefix":"10.12688","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2367-0179","authenticated-orcid":false,"given":"Isabel","family":"Ryan","sequence":"first","affiliation":[{"name":"Dublin Leinster Trinity College Dublin School of Pharmacy and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"McCarron","sequence":"additional","affiliation":[{"name":"Trinity Centre for Ageing and the Life Course in Intellectual Disability Dublin Leinster Trinity College Dublin School of Nursing and Midwifery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5129-6399","authenticated-orcid":false,"given":"Philip","family":"McCallion","sequence":"additional","affiliation":[{"name":"Philadelphia Pennsylvania Temple University School of Social Work"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3097-8048","authenticated-orcid":false,"given":"\u00c9ilish","family":"Burke","sequence":"additional","affiliation":[{"name":"Trinity Centre for Ageing and the Life Course in Intellectual Disability Dublin Leinster Trinity College Dublin School of Nursing and Midwifery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Mulryan","sequence":"additional","affiliation":[{"name":"Trinity Centre for Ageing and the Life Course in Intellectual Disability Dublin Leinster Trinity College Dublin School of Nursing and Midwifery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ire","family":"O'Dwyer","sequence":"additional","affiliation":[{"name":"Dublin Leinster Trinity College Dublin School of Pharmacy and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crist\u00edn","family":"Ryan","sequence":"additional","affiliation":[{"name":"Dublin Leinster Trinity College Dublin School of Pharmacy and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"O'Connell","sequence":"additional","affiliation":[{"name":"Dublin Leinster Trinity College Dublin School of Pharmacy and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"591-599","DOI":"10.1046\/j.1365-2788.2000.00280.x","article-title":"Life expectancy of people with intellectual disability: a 35-year follow-up study.","volume":"44","author":"K Patja","year":"2000 Oct 1","journal-title":"J. Intellect. Disabil. Res."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"6-16","DOI":"10.1002\/ddrr.1123","article-title":"People with intellectual disability: What do we know about adulthood and life expectancy?.","volume":"18","author":"A Coppus","year":"2013 Aug 1","journal-title":"Dev. Disabil. Res. Rev."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"889-895","DOI":"10.1016\/S0140-6736(13)62026-7","article-title":"The Confidential Inquiry into premature deaths of people with intellectual disabilities in the UK: a population-based study.","volume":"383","author":"P Heslop","year":"2014 Mar 8","journal-title":"Lancet."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"62-74","DOI":"10.1111\/jir.12314","article-title":"Mortality in people with intellectual disabilities in England.","volume":"61","author":"G Glover","year":"2017","journal-title":"J. Intellect. Disabil. Res."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"521-527","DOI":"10.1016\/j.ridd.2012.07.029","article-title":"Patterns of multimorbidity in an older population of persons with an intellectual disability: Results from the intellectual disability supplement to the Irish longitudinal study on aging (IDS-TILDA).","volume":"34","author":"M McCarron","year":"2013 Jan","journal-title":"Res. Dev. Disabil."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e0184390","DOI":"10.1371\/journal.pone.0184390","article-title":"Medication and supplement use in older people with and without intellectual disability: An observational, cross-sectional study. Forloni G, editor.","volume":"12","author":"J Peklar","year":"2017 Sep 6","journal-title":"PLoS ONE."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"776-783","DOI":"10.1016\/j.ridd.2014.01.022","article-title":"Multimorbidity in older adults with intellectual disabilities.","volume":"35","author":"H Hermans","year":"2014 Apr 1","journal-title":"Res. Dev. Disabil."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e010505","DOI":"10.1136\/bmjopen-2015-010505","article-title":"Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study.","volume":"6","author":"M O\u2019Dwyer","year":"2016 Apr","journal-title":"BMJ Open."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"72-82","DOI":"10.1352\/1944-7558-123.1.72","article-title":"Multimorbidity and Polypharmacy Are Independently Associated With Mortality in Older People With Intellectual Disabilities: A 5-Year Follow-Up From the HA-ID Study.","volume":"123","author":"J Schoufour","year":"2018 Jan 1","journal-title":"Am. J. Intellect. Dev. Disabil."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1656-1662","DOI":"10.1016\/j.ridd.2013.02.005","article-title":"Prescription errors in older individuals with an intellectual disability: Prevalence and risk factors in the Healthy Ageing and Intellectual Disability Study.","volume":"34","author":"R Zaal","year":"2013 May 1","journal-title":"Res. Dev. Disabil."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"482-492","DOI":"10.1002\/pds.4987","article-title":"Medication burden and frailty in older adults with intellectual disability: An observational cross-sectional study.","volume":"29","author":"J O\u2019Connell","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jar.70253","article-title":"Predicting Injuries in Adults With Intellectual Disabilities in Supported Living: Development and Validation of Risk Assessment Tools.","author":"E Petropoulou","year":"2026"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"985-994","DOI":"10.1080\/14740338.2022.2044786","article-title":"Associations between hyper-polypharmacy and potentially inappropriate prescribing with clinical and functional outcomes in older adults.","volume":"21","author":"A Mekonnen","year":"2022 Jul 3","journal-title":"Expert Opin. Drug Saf."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e008656","DOI":"10.1136\/bmjopen-2015-008656","article-title":"Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study.","volume":"5","author":"F Moriarty","year":"2015 Sep 1","journal-title":"BMJ Open."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"504-510","DOI":"10.1192\/bjp.bp.115.173971","article-title":"Association of anticholinergic burden with adverse effects in older people with intellectual disabilities: an observational cross-sectional study.","volume":"209","author":"M O\u2019Dwyer","year":"2016 Dec","journal-title":"Br. J. Psychiatry."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"553-567","DOI":"10.1111\/bcp.13479","article-title":"Drug burden index to define the burden of medicines in older adults with intellectual disabilities: An observational cross-sectional study.","volume":"84","author":"J O\u2019Connell","year":"2018 Mar","journal-title":"Brit J Clinical Pharma."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1284-1294","DOI":"10.1111\/jir.70018","article-title":"Ten-Year Outcomes of Anticholinergic Use Among Older Adults With Intellectual Disability: Findings From the Intellectual Disability Supplement to the Irish Longitudinal Study on Ageing (IDS-TILDA).","volume":"69","author":"L Al Shuhaimi","year":"2025","journal-title":"J. Intellect. Disabil. Res."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"463-477","DOI":"10.1111\/j.1365-2788.2006.00902.x","article-title":"Fifteen-year follow-up of 92 hospitalized adults with Down\u2019s syndrome: incidence of cognitive decline, its relationship to age and neuropathology.","volume":"51","author":"M Margallo-Lana","year":"2007 Jun","journal-title":"J. Intellect. Disabil. Res."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"264-267","DOI":"10.1111\/j.1365-2788.1997.tb00706.x","article-title":"Early menopause in women with Down\u2019s syndrome.","volume":"41","author":"N Schupf","year":"1997 Jun","journal-title":"J. Intellect. Disabil. Res."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"461-465","DOI":"10.1046\/j.1365-2788.1999.00192.x","article-title":"Age at onset of dementia and age of menopause in women with Down\u2019s syndrome.","volume":"43","author":"M Cosgrave","year":"1999 Dec","journal-title":"J. Intellect. Disabil. Res."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"166-171","DOI":"10.1080\/13668250600879222","article-title":"Menstrual profile and early menopause in women with Down syndrome aged 26-40 years.","volume":"31","author":"K Ejskjaer","year":"2006 Sep","journal-title":"J. Intellect. Develop. Disabil."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"165-77","DOI":"10.1002\/9780470697863.ch9","author":"R Winterhalder","year":"2008","journal-title":"Learning Disability and Other Intellectual Impairments."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e017406","DOI":"10.1136\/bmjopen-2017-017406","article-title":"Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study.","volume":"7","author":"R Sheehan","year":"2017 Aug 3","journal-title":"BMJ Open."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"981-993","DOI":"10.1111\/jar.12591","article-title":"Prevalence and patterns of antipsychotic use and their associations with mental health and problem behaviours among older adults with intellectual disabilities.","volume":"32","author":"C O\u2019Dwyer","year":"2019","journal-title":"J. Appl. Res. Intellect. Disabil."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"h4326","DOI":"10.1136\/bmj.h4326","article-title":"Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study.","author":"R Sheehan","year":"2015 Sep 1","journal-title":"BMJ."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"CD000377","DOI":"10.1002\/14651858.CD000377.pub2\/full","article-title":"Antipsychotic medication for challenging behaviour in people with learning disability.","volume":"2009","author":"J Brylewski","year":"2004 Jul 19 cited 2025 Dec 20","journal-title":"Cochrane Database of Systematic Reviews."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/pharmacy14010005","article-title":"Structured Medication Review and Shared Decision-Making in Patients with Mild Intellectual Disabilities Who Use Psychotropic Medication.","volume":"14","author":"G Kuijper","year":"2026 Feb","journal-title":"Pharmacy."},{"key":"ref28","article-title":"Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes.","year":"2015 cited 2025 Dec 17"},{"key":"ref29","doi-asserted-by":"publisher","article-title":"Clinical impact of medication review and deprescribing in older inpatients: A systematic review and meta-analysis.","author":"M Carollo","DOI":"10.1111\/jgs.19035"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2050312116652568","DOI":"10.1177\/2050312116652568","article-title":"The effect of pharmacist-led interventions in optimising prescribing in older adults in primary care: A systematic review.","volume":"4","author":"D Riordan","year":"2016 Jan 1","journal-title":"Sage Open Medicine."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e046630","DOI":"10.1136\/bmjopen-2020-046630","article-title":"Reducing risks associated with medicines and lifestyle in a residential care population with intellectual disabilities: evaluation of a pharmacy review initiative in England.","volume":"11","author":"N Thayer","year":"2021 Aug 17","journal-title":"BMJ Open."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2052-2081","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults.","volume":"71","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"625-632","DOI":"10.1007\/s41999-023-00777-y","article-title":"STOPP\/START criteria for potentially inappropriate prescribing in older people: version 3.","volume":"14","author":"D O\u2019Mahony","year":"2023 Aug","journal-title":"Eur Geriatr Med."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1389-1402","DOI":"10.1007\/s41999-025-01201-3","article-title":"Prevalence of potentially inappropriate prescribing in community-dwelling older adults: an application of STOPP\/START version 3 to The Irish Longitudinal Study on Ageing (TILDA).","volume":"16","author":"A Doherty","year":"2025","journal-title":"Eur Geriatr Med."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"535-557","DOI":"10.1177\/2042098618782785","article-title":"Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research.","volume":"9","author":"M O\u2019Dwyer","year":"2018 Sep","journal-title":"Therapeutic Advances in Drug Safety."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"649-652","DOI":"10.1080\/14740338.2020.1751119","article-title":"Measuring drug burden in older adults with intellectual disabilities: Critical issues for consideration in finding the optimal measure to improve safety of medicines use.","volume":"19","author":"M O\u2019Dwyer","year":"2020 Jun 2","journal-title":"Expert Opin. Drug Saf."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1521-1530","DOI":"10.1111\/j.1532-5415.2011.03497.x","article-title":"Comparison of Prescribing Criteria to Evaluate the Appropriateness of Drug Treatment in Individuals Aged 65 and Older: A Systematic Review.","volume":"59","author":"M Dimitrow","year":"2011","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"365-372","DOI":"10.1111\/j.1365-2788.1997.tb00723.x","article-title":"Primary health care and people with an intellectual disability: the evidence base.","volume":"41","author":"N Lennox","year":"1997","journal-title":"J. Intellect. Disabil. Res."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"837-851","DOI":"10.1080\/17512433.2024.2390913","article-title":"OPTIMA-ID: development and validation of a medicine optimization tool for older adults with intellectual disability.","volume":"17","author":"J O\u2019Connell","year":"2024 Sep","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref43","article-title":"2024 update: Building a more inclusive Australia. Australia\u2019s Disability Strategy 2021-2031.","year":"2025 Jun cited 2025 Dec 1"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1-24","DOI":"10.2147\/DHPS.S558001","article-title":"A Rapid Mapping Review of Medication Burden in Adults with an Intellectual Disability: What We Know and What We Do Not Know.","volume":"18","author":"S Marquis","year":"2026 Mar 11","journal-title":"DHPS."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"132-142","DOI":"10.1016\/j.ridd.2016.03.014","article-title":"Medication review using a Systematic Tool to Reduce Inappropriate Prescribing (STRIP) in adults with an intellectual disability: A pilot study.","volume":"55","author":"R Zaal","year":"2016 Aug 1","journal-title":"Res. Dev. Disabil."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"346-355","DOI":"10.1111\/jar.12183","article-title":"Structured Medication Review to Improve Pharmacotherapy in People with Intellectual Disability and Behavioural Problems.","volume":"29","author":"A Scheifes","year":"2016 Jul","journal-title":"Research Intellect Disabil."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e207-e214","DOI":"10.1111\/ajag.12900","article-title":"Potentially inappropriate medicines for older adults with intellectual disability: Clinical implications from a medication audit.","volume":"40","author":"A Lim","year":"2021","journal-title":"Australas. J. Ageing."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e039208","DOI":"10.1136\/bmjopen-2020-039208","article-title":"TOP-ID: a Delphi technique-guided development of a prescription and deprescription tool for adults with intellectual disabilities.","volume":"10","author":"S Lonchampt","year":"2020 Nov 1","journal-title":"BMJ Open."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"20420986251342351","DOI":"10.1177\/20420986251342351","article-title":"Developing and testing of an assessment tool for appropriate psychotropic drug prescribing in people with intellectual disabilities.","volume":"16","author":"J Jonker","year":"2025 Jul 8","journal-title":"Ther Adv Drug Saf."},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.20556000","article-title":"Application of OPTIMA-ID to identify potentially inappropriate prescribing in a cohort of older adults with intellectual disability.","author":"I Ryan","year":"2026","journal-title":"Zenodo."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"64-67","DOI":"10.3109\/09638288809164105","article-title":"The Barthel ADL Index: a standard measure of physical disability?.","volume":"10","author":"D Wade","year":"1988","journal-title":"Int. Disabil. Stud."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1192\/bjo.2023.607","article-title":"Psychotropic medicines\u2019 prevalence, patterns and effects on cognitive and physical function in older adults with intellectual disability in Ireland: longitudinal cohort study, 2009\u20132020.","volume":"10","author":"M Odalovi\u0107","year":"2024 Mar","journal-title":"BJPsych Open."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1373-1379","DOI":"10.1016\/s0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis.","volume":"49","author":"P Peduzzi","year":"1996 Dec","journal-title":"J. Clin. Epidemiol."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1516-1525","DOI":"10.1007\/s11096-019-00914-3","article-title":"Interdisciplinary medication review to improve pharmacotherapy for patients with intellectual disabilities.","volume":"41","author":"A Granas","year":"2019 Dec 1","journal-title":"Int. J. Clin. Pharm."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"103-111","DOI":"10.1111\/jir.13192","article-title":"Comparing self-report medication data from a longitudinal study on intellectual disability and national dispensing records.","volume":"69","author":"A Gorman","year":"2025","journal-title":"J. Intellect. Disabil. Res."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"573-577","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies.","volume":"147","author":"E Von Elm","year":"2007 Oct 16","journal-title":"Ann. Intern. Med."}],"container-title":["HRB Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/hrbopenresearch.org\/articles\/9-81\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/hrbopenresearch.org\/articles\/9-81\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/hrbopenresearch.org\/articles\/9-81\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:29:08Z","timestamp":1787117348000},"score":1,"resource":{"primary":{"URL":"https:\/\/hrbopenresearch.org\/articles\/9-81\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":53,"URL":"https:\/\/doi.org\/10.12688\/hrbopenres.14510.1","relation":{"has-review":[{"id-type":"doi","id":"10.21956\/hrbopenres.15993.r57024","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/hrbopenres.15993.r57027","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/hrbopenres.15993.r57027","asserted-by":"object"},{"id-type":"doi","id":"10.21956\/hrbopenres.15993.r57024","asserted-by":"object"}]},"ISSN":["2515-4826"],"issn-type":[{"value":"2515-4826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"Indexed","URL":"https:\/\/hrbopenresearch.org\/articles\/9-81\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.21956\/hrbopenres.15993.r57024, Steven R. Erickson, University of Michigan, Ann Arbor, 14 Aug 2026, version 1, indexed","URL":"https:\/\/hrbopenresearch.org\/articles\/9-81\/v1#referee-response-57024","order":0,"name":"referee-response-57024","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.21956\/hrbopenres.15993.r57027, Rory Sheehan, King\u2019s College London, London, 19 Aug 2026, version 1, indexed","URL":"https:\/\/hrbopenresearch.org\/articles\/9-81\/v1#referee-response-57027","order":1,"name":"referee-response-57027","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"IDS-TILDA is funded by the Health Research Board Ireland IDS-TILDA-2025-001 and supported by the Department of Children, Disability and Equality (DCDE). The authors acknowledge the support of the Panoz Pharmaceutical Innovation PhD Scholarship, awarded by the School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin. This scholarship was made possible through a generous bequest from the estate of Dr. Don Panoz. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}